| 谭利民
1
苏玉霞
2
汤明明
2
屠明强
2
杨 玮.双氯芬酸钠与塞来昔布治疗类风湿关节炎的疗效及对心血管的影响研究[J].现代生物医学进展英文版,2014,14(6):1124-1127. |
| 双氯芬酸钠与塞来昔布治疗类风湿关节炎的疗效及对心血管的影响研究 |
| The Clinical Effect of Diclofenac and Celecoxib in Treatment of RheumatoidArthritis and its Effect on the Cardiovascular |
| |
| DOI： |
| 中文关键词: 双氯芬酸钠 塞来昔布 类风湿关节炎 |
| 英文关键词: Diclofenac Celecoxib Rheumatoid Arthritis |
| 基金项目: |
|
| Hits: 757 |
| Download times: 1441 |
| 中文摘要: |
| 摘要 目的： 探讨双氯芬酸钠和塞来昔布治疗类风湿关节炎的临床疗效及用药安全性。方法： 将我院 2011 年 1 月 -2012 年 1 月门
诊收治的 98 例类风湿性关节炎患者随机分为对照组和观察组， 每组 49 例。对照组给予双氯芬酸钠治疗， 观察组给予塞来昔布治
疗， 观察两组临床治疗效果及心血管不良事件的发生情况。 结果： 观察组总有效率为 91.84%显著高于对照组的 75.51%， 两组比较
差异具有统计学意义 （P<0.05 ） ； 观察组 ESR 及 CRP 分别为（ 110.65± 7.28 ） mm/h 和 （10.42± 0.98 ） mg/L 显著低于治疗前和对照组，
比较差异具有统计学意义 （P<0.05 ） ； 观察组心血管不良事件发生率为 8.16%显著低于对照组的 20.41%， 两组比较差异具有统计
学意义 （P<0.05 ）。结论： 塞来昔布治疗类风湿关节炎具有较好的临床疗效， 可有效改善患者疼痛、 僵硬或功能受限等症状， 且心血
管不良事件发生率低， 值得临床进一步推广和应用。 |
| 英文摘要: |
| ABSTRACT Objective：To investigate the clinical efficacy and medication safety of diclofenac and celecoxib in the treatment of
rheumatoid arthritis. Methods:98 patients with the rheumatoid who were treated in our hospital from January 2011 to 2012 were selected
and randomly divided into the control group and the observation group with 49 cases in each one. The patients in the control group were
treated by the diclofenac, while the patients in the observation group were treated by the celecoxib. Then the clinical effect and the occurrence of adverse cardiovascular were observed and compared between two groups two groups.Results: In the observation group, the total
effective rate in the observation group was 91.84%, the ESR was (110.65 ± 7.28) mm/h and the CRP was (10.42 ± 0.98) mg/L which
were significantly different when comparing with the control group(P<0.05); the incidence of adverse cardiovascular events of patients in
the observation group was 8.16% which was significantly lower than 20.41% in the control group (P<0.05).Conclusion: It is indicated
that the effects of Celecoxib on the treatment of rheumatoid arthritis should be worthy to be promoted to the clinical with the advantages
of better efficacy, and low incidence of adverse cardiovascular reactions |
|
View Full Text
View/Add Comment Download reader |
| Close |
